Literature DB >> 11944762

Latent tuberculosis infection: old problem, new priorities.

Kevin Schwartzman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11944762      PMCID： PMC99454     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  21 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations.

Authors:  K Dasgupta; K Schwartzman; R Marchand; T N Tennenbaum; P Brassard; D Menzies
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

3.  Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy.

Authors:  D E Snider; G J Caras; J P Koplan
Journal:  JAMA       Date:  1986-03-28       Impact factor: 56.272

4.  Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study.

Authors:  C M Nolan; A M Elarth
Journal:  Am Rev Respir Dis       Date:  1988-04

5.  Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.

Authors:  F Gordin; R E Chaisson; J P Matts; C Miller; M de Lourdes Garcia; R Hafner; J L Valdespino; J Coberly; M Schechter; A J Klukowicz; M A Barry; R J O'Brien
Journal:  JAMA       Date:  2000-03-15       Impact factor: 56.272

6.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

7.  Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-08-31       Impact factor: 17.586

8.  Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis.

Authors:  K Schwartzman; D Menzies
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

9.  Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

10.  Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area.

Authors:  O Horwitz; E Wilbek; P A Erickson
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408
View more
  3 in total

1.  Latent tuberculosis treatment.

Authors:  Stan Houston; Richard Long; Vernon Hoeppner
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

2.  Guidelines for the investigation and follow-up of individuals under medical surveillance for tuberculosis after arriving in Canada: a summary.

Authors:  Neil Heywood; Barbara Kawa; Richard Long; Howard Njoo; Linda Panaro; Wendy Wobeser
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

3.  Adverse events associated with treatment of latent tuberculosis in the general population.

Authors:  Benjamin M Smith; Kevin Schwartzman; Gillian Bartlett; Dick Menzies
Journal:  CMAJ       Date:  2011-01-10       Impact factor: 8.262
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.